Incyte INCY
NASDAQ INCY
$127.42 -0.58 (-0.45%)
As of: Sep 4, 2026 · 11:51 AM EDT

Incyte (INCY) Profit After Tax (2010 - 2026)

Incyte's (INCY) quarterly Profit After Tax came in at $585.6 million in Q2 2026, up 44.59% YoY from $405.0 million in Q2 2025, and up 93.06% on a QoQ basis from $303.3 million in Q1 2026.

Analysis

Incyte (INCY) Profit After Tax (2010 - 2026) Analysis & Trends

Incyte (INCY) has 17 years of Profit After Tax data on file, last reported at $585.6 million in Q2 2026.

  • Quarterly Profit After Tax rose 44.59% year-over-year to $585.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.6 billion (up 85.15% YoY) and the FY2025 annual result came in at $1.3 billion, up 3844.96% from the prior year.
  • Profit After Tax climbed to $585.6 million in Q2 2026, from $303.3 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $585.6 million in Q2 2026 to a low of -$444.6 million in Q2 2024.
  • A 5-year average of $174.8 million and a median of $170.4 million in 2023 frame the typical range for Profit After Tax.
  • The widest YoY moves for Profit After Tax: up 681.22% in 2024, down 318.43% in 2024.
  • Tracing INCY's Profit After Tax over 5 years: stood at $28.5 million in 2022, then jumped by 606.51% to $201.1 million in 2023, then climbed by 0.07% to $201.2 million in 2024, then surged by 48.74% to $299.3 million in 2025, then jumped by 95.67% to $585.6 million in 2026.
  • The last three Profit After Tax figures came in at $585.6 million (Q2 2026), $303.3 million (Q1 2026), and $299.3 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT (Qtr)
1 Vertex Pharmaceuticals 140.22 Bn 132.37 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 86.04 Bn 78.05 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.70 Bn 58.52 Bn 1.37 Bn 472.00 Mn
4 Moderna 57.56 Bn 52.42 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.05 Bn 44.05 Bn - -644.37 Mn
6 BeOne Medicines 40.16 Bn 35.06 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.63 Bn 32.32 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.63 Bn 27.79 Bn - 81.49 Mn
9 Insmed 27.73 Bn 26.57 Bn 358.27 Mn -16.62 Mn
10 Incyte 25.60 Bn 21.07 Bn 1.57 Bn 585.61 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 585.61 Mn
Mar 31, 2026 303.33 Mn
Dec 31, 2025 299.28 Mn
Sep 30, 2025 424.17 Mn
Jun 30, 2025 405.00 Mn
Mar 31, 2025 158.20 Mn
Dec 31, 2024 201.21 Mn
Sep 30, 2024 106.46 Mn
Jun 30, 2024 -444.60 Mn
Mar 31, 2024 169.55 Mn
Dec 31, 2023 201.08 Mn
Sep 30, 2023 171.27 Mn
Jun 30, 2023 203.55 Mn
Mar 31, 2023 21.70 Mn
Dec 31, 2022 28.46 Mn
Sep 30, 2022 112.78 Mn
Jun 30, 2022 161.43 Mn
Mar 31, 2022 37.99 Mn
Dec 31, 2021 563.85 Mn
Sep 30, 2021 181.74 Mn